Milestone Pharmaceuticals (MIST) Competitors

$1.43 -0.03 (-2.05%)

Closing price 04:00 PM Eastern

Extended Trading

$1.48 +0.05 (+3.15%)

As of 06:17 PM Eastern

MIST vs. AMPH, SPRY, RLMD, EIKN, and SLDB

Should you buy Milestone Pharmaceuticals stock or one of its competitors? MarketBeat compares Milestone Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Milestone Pharmaceuticals include Amphastar Pharmaceuticals (AMPH), ARS Pharmaceuticals (SPRY), Relmada Therapeutics (RLMD), EIKN (EIKN), and Solid Biosciences (SLDB). These companies are all part of the "pharmaceutical products" industry.

How does Milestone Pharmaceuticals compare to Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are held by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are held by insiders. Comparatively, 19.5% of Milestone Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Amphastar Pharmaceuticals has a net margin of 11.00% compared to Milestone Pharmaceuticals' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 15.12% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%
Milestone Pharmaceuticals	N/A	-339.33%	-61.79%

Amphastar Pharmaceuticals has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market. Comparatively, Milestone Pharmaceuticals has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market.

Amphastar Pharmaceuticals currently has a consensus price target of $24.50, indicating a potential upside of 37.49%. Milestone Pharmaceuticals has a consensus price target of $7.25, indicating a potential upside of 406.99%. Given Milestone Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amphastar Pharmaceuticals	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88
Milestone Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50

Amphastar Pharmaceuticals has higher revenue and earnings than Milestone Pharmaceuticals. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amphastar Pharmaceuticals	$719.89M	1.09	$98.09M	$1.66	10.73
Milestone Pharmaceuticals	$1.55M	114.86	-$63.06M	-$0.68	N/A

In the previous week, Milestone Pharmaceuticals had 16 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 25 mentions for Milestone Pharmaceuticals and 9 mentions for Amphastar Pharmaceuticals. Amphastar Pharmaceuticals' average media sentiment score of 0.05 beat Milestone Pharmaceuticals' score of 0.00 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amphastar Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Milestone Pharmaceuticals	5 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Amphastar Pharmaceuticals beats Milestone Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Milestone Pharmaceuticals compare to ARS Pharmaceuticals?

ARS Pharmaceuticals (NASDAQ:SPRY) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

In the previous week, Milestone Pharmaceuticals had 14 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 25 mentions for Milestone Pharmaceuticals and 11 mentions for ARS Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 0.00 beat Milestone Pharmaceuticals' score of 0.00 indicating that ARS Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ARS Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Milestone Pharmaceuticals	5 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ARS Pharmaceuticals has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market. Comparatively, Milestone Pharmaceuticals has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market.

Milestone Pharmaceuticals has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -200.00%. ARS Pharmaceuticals' return on equity of -130.75% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	-200.00%	-130.75%	-58.58%
Milestone Pharmaceuticals	N/A	-339.33%	-61.79%

68.2% of ARS Pharmaceuticals shares are held by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are held by institutional investors. 33.8% of ARS Pharmaceuticals shares are held by insiders. Comparatively, 19.5% of Milestone Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

ARS Pharmaceuticals currently has a consensus price target of $28.25, suggesting a potential upside of 294.00%. Milestone Pharmaceuticals has a consensus price target of $7.25, suggesting a potential upside of 406.99%. Given Milestone Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Milestone Pharmaceuticals is more favorable than ARS Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Milestone Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50

Milestone Pharmaceuticals has lower revenue, but higher earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$98.99M	7.19	-$171.30M	-$2.01	N/A
Milestone Pharmaceuticals	$1.55M	114.86	-$63.06M	-$0.68	N/A

Summary

Milestone Pharmaceuticals beats ARS Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Milestone Pharmaceuticals compare to Relmada Therapeutics?

Relmada Therapeutics (NASDAQ:RLMD) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.

Relmada Therapeutics has a beta of 0.43, suggesting that its stock price is 57% less volatile than the broader market. Comparatively, Milestone Pharmaceuticals has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market.

Relmada Therapeutics currently has a consensus target price of $12.00, indicating a potential upside of 70.70%. Milestone Pharmaceuticals has a consensus target price of $7.25, indicating a potential upside of 406.99%. Given Milestone Pharmaceuticals' higher possible upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than Relmada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Milestone Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50

45.2% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 14.5% of Relmada Therapeutics shares are owned by insiders. Comparatively, 19.5% of Milestone Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Milestone Pharmaceuticals had 20 more articles in the media than Relmada Therapeutics. MarketBeat recorded 25 mentions for Milestone Pharmaceuticals and 5 mentions for Relmada Therapeutics. Milestone Pharmaceuticals' average media sentiment score of 0.00 beat Relmada Therapeutics' score of -0.16 indicating that Milestone Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relmada Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Milestone Pharmaceuticals	5 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Relmada Therapeutics has higher earnings, but lower revenue than Milestone Pharmaceuticals. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A
Milestone Pharmaceuticals	$1.55M	114.86	-$63.06M	-$0.68	N/A

Relmada Therapeutics' return on equity of -71.22% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-71.22%	-64.46%
Milestone Pharmaceuticals	N/A	-339.33%	-61.79%

Summary

Milestone Pharmaceuticals beats Relmada Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Milestone Pharmaceuticals compare to EIKN?

EIKN (NASDAQ:EIKN) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership.

EIKN's return on equity of 0.00% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
EIKN	N/A	N/A	N/A
Milestone Pharmaceuticals	N/A	-339.33%	-61.79%

EIKN has higher earnings, but lower revenue than Milestone Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EIKN	N/A	N/A	N/A	N/A	N/A
Milestone Pharmaceuticals	$1.55M	114.86	-$63.06M	-$0.68	N/A

In the previous week, Milestone Pharmaceuticals had 23 more articles in the media than EIKN. MarketBeat recorded 25 mentions for Milestone Pharmaceuticals and 2 mentions for EIKN. EIKN's average media sentiment score of 0.11 beat Milestone Pharmaceuticals' score of 0.00 indicating that EIKN is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
EIKN	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Milestone Pharmaceuticals	5 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 19.5% of Milestone Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

EIKN presently has a consensus price target of $25.20, indicating a potential upside of 136.84%. Milestone Pharmaceuticals has a consensus price target of $7.25, indicating a potential upside of 406.99%. Given Milestone Pharmaceuticals' higher probable upside, analysts plainly believe Milestone Pharmaceuticals is more favorable than EIKN.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
EIKN	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Milestone Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Milestone Pharmaceuticals beats EIKN on 6 of the 11 factors compared between the two stocks.

How does Milestone Pharmaceuticals compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations, dividends and media sentiment.

Solid Biosciences currently has a consensus price target of $16.36, indicating a potential upside of 169.14%. Milestone Pharmaceuticals has a consensus price target of $7.25, indicating a potential upside of 406.99%. Given Milestone Pharmaceuticals' higher possible upside, analysts plainly believe Milestone Pharmaceuticals is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Milestone Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50

Milestone Pharmaceuticals has higher revenue and earnings than Solid Biosciences. Solid Biosciences is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A
Milestone Pharmaceuticals	$1.55M	114.86	-$63.06M	-$0.68	N/A

In the previous week, Milestone Pharmaceuticals had 20 more articles in the media than Solid Biosciences. MarketBeat recorded 25 mentions for Milestone Pharmaceuticals and 5 mentions for Solid Biosciences. Milestone Pharmaceuticals' average media sentiment score of 0.00 beat Solid Biosciences' score of -0.39 indicating that Milestone Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Milestone Pharmaceuticals	5 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Solid Biosciences has a beta of 2.47, suggesting that its share price is 147% more volatile than the broader market. Comparatively, Milestone Pharmaceuticals has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market.

81.5% of Solid Biosciences shares are owned by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 13.6% of Solid Biosciences shares are owned by company insiders. Comparatively, 19.5% of Milestone Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Solid Biosciences' return on equity of -73.42% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-73.42%	-61.13%
Milestone Pharmaceuticals	N/A	-339.33%	-61.79%

Summary

Milestone Pharmaceuticals beats Solid Biosciences on 9 of the 14 factors compared between the two stocks.

Get Milestone Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MIST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MIST vs. The Competition

Export

Metric	Milestone Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$178.04M	$3.25B	$6.25B	$12.10B
Dividend Yield	N/A	2.33%	2.80%	5.32%
P/E Ratio	-2.10	18.70	20.58	25.11
Price / Sales	114.86	278.20	577.42	91.32
Price / Cash	N/A	55.27	27.48	37.30
Price / Book	3.67	6.57	9.68	6.60
Net Income	-$63.06M	$24.30M	$3.55B	$335.71M
7 Day Performance	-24.74%	-3.56%	-2.07%	-2.03%
1 Month Performance	-31.90%	-7.86%	-3.90%	-1.90%
1 Year Performance	10.85%	51.80%	29.39%	27.36%

Milestone Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MIST Milestone Pharmaceuticals	2.5547 of 5 stars	$1.43 -2.1%	$7.25 +407.0%	+19.7%	$178.04M	$1.55M	N/A	30	Earnings Report Analyst Downgrade Analyst Revision
AMPH Amphastar Pharmaceuticals	4.1484 of 5 stars	$17.20 +2.0%	$24.50 +42.4%	-30.8%	$743.85M	$719.89M	10.36	1,976
SPRY ARS Pharmaceuticals	2.8176 of 5 stars	$7.30 -1.7%	$28.25 +287.0%	-46.3%	$737.31M	$98.99M	N/A	90	Earnings Report Analyst Upgrade
RLMD Relmada Therapeutics	2.6016 of 5 stars	$6.34 -8.1%	$12.00 +89.3%	+1,275.3%	$723.74M	N/A	N/A	10	Earnings Report High Trading Volume
EIKN EIKN	N/A	$11.75 -11.3%	$25.20 +114.5%	N/A	$717.34M	N/A	N/A	384	News Coverage High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MIST) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Milestone Pharmaceuticals (MIST) Competitors

MIST vs. AMPH, SPRY, RLMD, EIKN, and SLDB

How does Milestone Pharmaceuticals compare to Amphastar Pharmaceuticals?

Summary

How does Milestone Pharmaceuticals compare to ARS Pharmaceuticals?

Summary

How does Milestone Pharmaceuticals compare to Relmada Therapeutics?

Summary

How does Milestone Pharmaceuticals compare to EIKN?

Summary

How does Milestone Pharmaceuticals compare to Solid Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIST vs. The Competition

Milestone Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Milestone Pharmaceuticals (MIST) Competitors

MIST vs. AMPH, SPRY, RLMD, EIKN, and SLDB

How does Milestone Pharmaceuticals compare to Amphastar Pharmaceuticals?

Do institutionals and insiders believe in AMPH or MIST?

Is AMPH or MIST more profitable?

Which has more volatility & risk, AMPH or MIST?

Do analysts rate AMPH or MIST?

Which has stronger earnings and valuation, AMPH or MIST?

Does the media favor AMPH or MIST?

Summary

How does Milestone Pharmaceuticals compare to ARS Pharmaceuticals?

Does the media favor SPRY or MIST?

Which has more volatility & risk, SPRY or MIST?

Is SPRY or MIST more profitable?

Do insiders & institutionals hold more shares of SPRY or MIST?

Do analysts recommend SPRY or MIST?

Which has better valuation and earnings, SPRY or MIST?

Summary

How does Milestone Pharmaceuticals compare to Relmada Therapeutics?

Which has more volatility and risk, RLMD or MIST?

Do analysts prefer RLMD or MIST?

Do insiders and institutionals believe in RLMD or MIST?

Does the media favor RLMD or MIST?

Which has preferable valuation and earnings, RLMD or MIST?

Is RLMD or MIST more profitable?

Summary

How does Milestone Pharmaceuticals compare to EIKN?

Is EIKN or MIST more profitable?

Which has higher valuation & earnings, EIKN or MIST?

Does the media refer more to EIKN or MIST?

Do institutionals and insiders have more ownership in EIKN or MIST?

Do analysts prefer EIKN or MIST?

Summary

How does Milestone Pharmaceuticals compare to Solid Biosciences?

Do analysts recommend SLDB or MIST?

Which has higher earnings & valuation, SLDB or MIST?

Does the media prefer SLDB or MIST?

Which has more volatility & risk, SLDB or MIST?

Do institutionals & insiders have more ownership in SLDB or MIST?

Is SLDB or MIST more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIST vs. The Competition

Milestone Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools